Trials / Completed
CompletedNCT04322266
A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.
An Open-Label, Randomized, Single-Dose Crossover Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
An Open-Label, Randomized, Single-Dose Crossover Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP1701 | Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium |
| DRUG | HCP1306 | Ezetimibe /Rosuvastatin |
| DRUG | HGP0904 | Amlodipine |
| DRUG | HGP0608 | Losartan potassium |
Timeline
- Start date
- 2018-12-21
- Primary completion
- 2019-02-13
- Completion
- 2019-02-13
- First posted
- 2020-03-26
- Last updated
- 2020-03-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04322266. Inclusion in this directory is not an endorsement.